Literature DB >> 26248514

Mitochondrion as a Target for Heart Failure Therapy- Role of Protein Lysine Acetylation.

Chi Fung Lee1, Rong Tian.   

Abstract

Heart failure is a leading cause of death worldwide. Despite medical advances, the dismal prognosis of heart failure has not been improved. The heart is a high energy-demanding organ. Impairments of cardiac energy metabolism and mitochondrial function are intricately linked to cardiac dysfunction. Mitochondrial dysfunction contributes to impaired myocardial energetics and increased oxidative stress in heart failure, and the opening of mitochondrial permeability transition pore triggers cell death and myocardial remodeling. Therefore, there has been growing interest in targeting mitochondria and metabolism for heart failure therapy. Recent developments suggest that mitochondrial protein lysine acetylation modulates the sensitivity of the heart to stress and hence the propensity to heart failure. This article reviews the role of mitochondrial dysfunction in heart failure, with a special emphasis on the regulation of the nicotinamide adenine dinucleotide (NAD(+)/NADH) ratio and sirtuin-dependent lysine acetylation by mitochondrial function. Strategies for targeting NAD(+)-sensitive mechanisms in order to intervene in protein lysine acetylation and, thereby, improve stress tolerance, are described, and their usefulness in heart failure therapy is discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26248514     DOI: 10.1253/circj.CJ-15-0742

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  19 in total

1.  Failed Power Plant Turns Into Mass Murder: New Insight on Mitochondrial Cardiomyopathy.

Authors:  Chi Fung Lee; Yang Cao; Rong Tian
Journal:  Circ Res       Date:  2018-01-05       Impact factor: 17.367

2.  Loss of cardiac carnitine palmitoyltransferase 2 results in rapamycin-resistant, acetylation-independent hypertrophy.

Authors:  Andrea S Pereyra; Like Y Hasek; Kate L Harris; Alycia G Berman; Frederick W Damen; Craig J Goergen; Jessica M Ellis
Journal:  J Biol Chem       Date:  2017-09-15       Impact factor: 5.157

3.  Raising NAD in Heart Failure: Time to Translate?

Authors:  Matthew A Walker; Rong Tian
Journal:  Circulation       Date:  2018-05-22       Impact factor: 29.690

Review 4.  The CD38 glycohydrolase and the NAD sink: implications for pathological conditions.

Authors:  Julianna D Zeidler; Kelly A Hogan; Guillermo Agorrody; Thais R Peclat; Sonu Kashyap; Karina S Kanamori; Lilian Sales Gomez; Delaram Z Mazdeh; Gina M Warner; Katie L Thompson; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Am J Physiol Cell Physiol       Date:  2022-02-09       Impact factor: 4.249

5.  Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy.

Authors:  Nicolas Diguet; Samuel A J Trammell; Cynthia Tannous; Robin Deloux; Jérôme Piquereau; Nathalie Mougenot; Anne Gouge; Mélanie Gressette; Boris Manoury; Jocelyne Blanc; Marie Breton; Jean-François Decaux; Gareth G Lavery; István Baczkó; Joffrey Zoll; Anne Garnier; Zhenlin Li; Charles Brenner; Mathias Mericskay
Journal:  Circulation       Date:  2017-12-07       Impact factor: 29.690

Review 6.  Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases.

Authors:  Juan Li; Tongxin Wang; Jun Xia; Weilei Yao; Feiruo Huang
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

Review 7.  Emerging potential benefits of modulating NAD+ metabolism in cardiovascular disease.

Authors:  Daniel S Matasic; Charles Brenner; Barry London
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

8.  Normalization of NAD+ Redox Balance as a Therapy for Heart Failure.

Authors:  Chi Fung Lee; Juan D Chavez; Lorena Garcia-Menendez; Yongseon Choi; Nathan D Roe; Ying Ann Chiao; John S Edgar; Young Ah Goo; David R Goodlett; James E Bruce; Rong Tian
Journal:  Circulation       Date:  2016-08-03       Impact factor: 29.690

9.  NAD+ Repletion Reverses Heart Failure With Preserved Ejection Fraction.

Authors:  Dan Tong; Gabriele G Schiattarella; Nan Jiang; Francisco Altamirano; Pamela A Szweda; Abdallah Elnwasany; Dong I Lee; Heesoo Yoo; David A Kass; Luke I Szweda; Sergio Lavandero; Eric Verdin; Thomas G Gillette; Joseph A Hill
Journal:  Circ Res       Date:  2021-04-22       Impact factor: 23.213

10.  Sirt1 improves heart failure through modulating the NF-κB p65/microRNA-155/BNDF signaling cascade.

Authors:  Bin Lin; Hui Zhao; Li Li; Zhenzhen Zhang; Nan Jiang; Xiaowei Yang; Tao Zhang; Bowen Lian; Yaokai Liu; Chi Zhang; Jiaxiang Wang; Feng Wang; Deguang Feng; Jing Xu
Journal:  Aging (Albany NY)       Date:  2020-11-18       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.